Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Refractory Status Epilepticus
Arch Neurol 59:205-210,188, Mayer,S.A.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
Functional Deficits in Patients with Mild Cognitive Impairment
Neurol 58:758-764, Tabert,M.H.,et al, 2002
Sandlike Appearance of Virchow-Robin Spaces in Early Multiple Sclerosis:A Novel Neuroradiologic Marker
AJNR 23:376-380, Achiron,A.&Faibel,M., 2002
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Euthanasia and Physician-Assisted Suicide Among Patients with Amyotrophic Lateral Sclerosis in the Netherlands
NEJM 346:1638-1644, Veldink,J.H.,et al, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging
Radiology 223:46-56, Bot,J.C.J.,et al, 2002
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Acquired Sexual Parphilia in Patients with Multiple Sclerosis
Arch Neurol 59:1006-1010, Frohman,E.M.,et al, 2002
Multiple Sclerosis
Lancet 359:1221-1231, Compston,A. &Coles,A., 2002
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Patients with Multiple Sclerosis and Risk of Type 1 Diabetes Mellitus in Sardinia,Italy: A Cohort Study
Lancet 359:1461-1465,1450, Marrosu,M.G.,et al, 2002
Bilateral Carotid Dissection. A Not to Underestmiate Cause of Neurological Loss After Road Accident
Unfallchirurg 105:919-922, Stock,K.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Outcome of and Prognostic Factors for Herpes Simplex Encephalitis in Adult Patients: Results of a Multicenter Study
Clin Inf Dis 35:254-260, Raschillas, F.,et al, 2002
Traumatic Bilateral Carotid Dissection with Concomitant Cerebral Infarction
J Emerg Med 20:33-38, Pittock,S.J.,et al, 2001
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Surgical Therapy for Tremor in Multiple Sclerosis
Neurol 57:1876-1882, Matsumoto,J.,et al, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001
Problems With Diagnositc Criteria for Multiple Sclerosis
Lancet 358:1746-1747, Poser,C.M. &Brinar,V.V., 2001
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
La Crosse Encephalitis in Children
NEJM 344:801-807, McJunkin,J.E.,et al, 2001
The Influence of Cognitive Impairment on Driving Performance in Multiple Sclerosis
Neurol 56:1089-1094, Schultheis,M.R.,et al, 2001
Evolution of Apparent Diffusion Coefficient, Diffusion-weighted, and T2-weighted Signal Intensity of Acute Stroke
AJNR 22:637-644, Lansberg,M.G.,et al, 2001
Linear Pontine Trigeminal Root Lesions in Multiple Sclerosis
Arch Neurol 58:101-104, Nakashima,I.,et al, 2001
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Evolution of MR Contrast Enhancement Patterns During the First Week after Acute Ischemic Stroke
AJNR 22:103-111, Karonen,J.O.,et al, 2001
APOE Genotype is a Major Predictor of Long-Term Progression of Disability in MS
Neurol 56:312-316, Chapman,J.,et al, 2001
Hepatitis B Vaccination and the Risk of Multiple Sclerosis
NEJM 344:327-332,372,381, Ascherio,A.,et al, 2001
Vaccinations and the Risk of Relapse in Multiple Sclerosis
NEJM 344:319-326,372, Confavreux,C.,et al, 2001
Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies
Arch Neurol 58:225-230, Honorat,J.,et al, 2001
Clinical and Neuroradiologic Features of Acute Disseminated Encephalomyelitis in Children
Neurol 56:1308-1312,1257, Hynson,J.L.,et al, 2001
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
European/Canadian Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Glatiramer Acetate on Magnetic Resonance Imaging-Measured Disease Activity and Burden in Patients wi
Ann Neurol 49:290-297, Comi,G.,et al, 2001
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
NEJM 344:710-719,763, Freed,C.R.,et al, 2001
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
CSF Oligoclonal Bands in MS Include Antibodies Against Chlamydophila Antigens
Neurol 56:1168-1176,1126,1128,1130, Yao,S.,et al, 2001
Presence of Chlamydia pneumoniae DNA in the Cerebral Spinal Fluid is a Common Phenomenon in a Variety of Neurological Diseases and Not Restricted to Multiple Sclerosis
Ann Neurol 49:585-589,556, Gieffers,J.,et al, 2001
Disability and Quality of Life in Charcot-Marie-Tooth Disease Type 1
JNNP 70:548-550, Pfeiffer,G.,et al, 2001
Evolution of Cerebral Infarct Volume Assessed by Diffusion-Weighted Magnetic Resonance Imaging
Arch Neurol 58:613-617, Lansberg,M.,G.,et al, 2001
Handicap After Acute Whiplash Injury
Neurol 56:1637-1643, Kasch,H.,et al, 2001
Acute Motor Radiculopathy as a First Symptom of MS: Anatomic-radiologic Correlation
Neurol 56:1603-1604, Lavallee,P.,et al, 2001
A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions
Ann Neurol 49:793-796, Bitsch,A.,et al, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001